A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

Trial Profile

A Double-blind, Randomized, Vehicle-controlled, Parallel-group, Phase II Dose-ranging Study to Evaluate the Efficacy and Safety of SR-T100 Gel in Common Warts (CW) Patients

Withdrawn prior to enrolment
Phase of Trial: Phase II

Latest Information Update: 04 Aug 2017

At a glance

  • Drugs SR T100 (Primary)
  • Indications Warts
  • Focus Therapeutic Use
  • Sponsors G&E Herbal Biotechnology
  • Most Recent Events

    • 31 Jul 2017 Planned initiation date changed from 1 May 2016 to 1 Jun 2016.
    • 31 Jul 2017 Status changed from not yet recruiting to withdrawn prior to enrolment due to budget issue.
    • 20 Jun 2014 According to ClinicalTrials.gov record, the age group was changed from 6 years and above to 17 years and above.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top